NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
Clinical Trials
27 trialsNCT02772588 2026-01-27
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT01961843 2025-11-25
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Massachusetts General Hospital
Phase NA Completed
NCT05177042 2025-07-25
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arvinas Inc.
Phase 1 Completed
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT01848067 2025-05-04
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
Phase 1/2 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT04207255 2024-09-25
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Phase 2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT04628988 2023-09-13
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Celgene
Phase 1 Completed
NCT03569280 2023-07-18
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Kangpu Biopharmaceuticals, Ltd.
Phase 1 Completed
NCT02789878 2022-09-15
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02867020 2021-07-07
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT02883166 2020-12-07
SNACK
Radboud University Medical Center
Phase 1 Completed
NCT02036060 2020-11-16
ABIDO
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT01553188 2019-03-05
AMG 386 and Abiraterone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01677897 2019-03-05
MetAb-Pro
Kantonsspital Graubünden
Phase 2 Completed
NCT01756638 2017-10-23
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT00924469 2013-04-17
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed